ClinicalTrials.gg

Program

trichostatin A

Its studies are mostly in Hematologic Neoplasms · Onychomycosis, led by Vanda Pharmaceuticals.

Furthest: phase 2, since Jun 5, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vanda Pharmaceuticals22 open or runningphase 2since Jun 5, 2025Feb 11, 2019Dec 2027phase 1 · NCT03838926

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2019First study: phase 1 study in RecurrenceFirst studyNCT03838926 · 42 planned · United States, Poland
  2. Jun 5, 2025Phase 2 study in OnychomycosisNCT07065773 · 50 enrolled · United States

Ahead

  1. Dec 2027Primary completion: phase 1 study in RecurrenceNCT03838926

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07065773Onychomycosis · United States2Active, not recruitingSep 202650
NCT03838926Recurrence · United States, Poland1RecruitingDec 202742

How it is read

Names in the registry

  • “Trichostatin A”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.